Topics

FDA Grants Priority Review to Avapritinib for GIST

17:44 EDT 7 Aug 2019 | OncLive

The FDA has granted a priority review designation to a new drug application for avapritinib for the treatment of adult patients with PDGFRA exon 18–mutant gastrointestinal stromal tumors, regardless of prior therapy, as well as for patients with GIST in the fourth-line setting.

Original Article: FDA Grants Priority Review to Avapritinib for GIST

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Avapritinib for GIST"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...